--- title: "Do Upbeat Estimate Revisions Signal a Durable Shift in Globe Life’s Earnings Power (GL)?" type: "News" locale: "en" url: "https://longbridge.com/en/news/289667312.md" description: "Globe Life (GL) is highlighted as a momentum stock by Zacks due to upward earnings estimate revisions and strong performance. The company raised its 2026 full-year earnings guidance to $15.40-$15.90 per diluted share following better Q1 results. While analysts are reassessing its earnings power, regulatory and legal overhangs from DOJ and SEC investigations remain key risks. Analysts project $6.8 billion revenue and $1.3 billion earnings by 2028." datetime: "2026-06-13T13:32:55.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/289667312.md) - [en](https://longbridge.com/en/news/289667312.md) - [zh-HK](https://longbridge.com/zh-HK/news/289667312.md) --- # Do Upbeat Estimate Revisions Signal a Durable Shift in Globe Life’s Earnings Power (GL)? - In recent days, Globe Life has been highlighted by Zacks as a momentum stock with a Rank of #2 and a Momentum Style Score of B, backed by upward revisions to earnings estimates and stronger recent performance than its industry and the S&P 500. - This combination of positive estimate revisions and relative strength suggests analysts are reassessing Globe Life’s earnings power, with sentiment increasingly aligned around its current business outlook. - We’ll now examine how these upward earnings estimate revisions may influence Globe Life’s existing investment narrative and longer-term outlook. Capitalize on the AI infrastructure supercycle with our selection of the 48 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow. ## Globe Life Investment Narrative Recap To own Globe Life, you need to be comfortable with a slower growing, agent-centric insurer that aims to turn steady underwriting and investment income into consistent earnings. The key near term catalyst is how effectively management converts the recent earnings guidance increase into sustained profit delivery, while the biggest risk remains regulatory and legal overhangs that could affect margins. The latest Zacks momentum call, driven by earnings estimate revisions, reinforces this catalyst but does not materially change the core risk profile. The most relevant recent announcement is Globe Life’s April 22 raise in full year 2026 earnings guidance to US$15.40 to US$15.90 per diluted share, following higher Q1 revenue and net income. This is the same earnings power that analysts upgrading their estimates are reacting to, so the Zacks momentum spotlight effectively echoes what the company has already signaled about its near term earnings trajectory and supports the idea that guidance credibility is a central catalyst. Yet behind the momentum headlines, the ongoing DOJ and SEC investigations remain an important overhang that investors should be aware of if... Read the full narrative on Globe Life (it's free!) Globe Life's narrative projects $6.8 billion revenue and $1.3 billion earnings by 2028. This requires 5.1% yearly revenue growth and about a $0.2 billion earnings increase from $1.1 billion today. Uncover how Globe Life's forecasts yield a $172.10 fair value, a 3% upside to its current price. ## Exploring Other Perspectives GL 1-Year Stock Price Chart Some of the most optimistic analysts already projected Globe Life could reach about US$7.6 billion in revenue and US$1.4 billion in earnings, but compared with concerns about rising health claims, the latest earnings estimate upgrades may prompt you to rethink how confident you are in that more bullish story and consider how different investors’ expectations can really be. Explore 3 other fair value estimates on Globe Life - why the stock might be worth over 2x more than the current price! ## Form Your Own Verdict Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts. - A great starting point for your Globe Life research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision. - Our free Globe Life research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Globe Life's overall financial health at a glance. ## Curious About Other Options? These stocks are moving-our analysis flagged them today. Act fast before the price catches up: - Outshine the giants: these 14 early-stage AI stocks could fund your retirement. - Uncover the next big thing with 24 elite penny stocks that balance risk and reward. - Find 44 companies with promising cash flow potential yet trading below their fair value. _This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned._ ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [GL.US](https://longbridge.com/en/quote/GL.US.md) - [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md) - [GL-D.US](https://longbridge.com/en/quote/GL-D.US.md) ## Related News & Research - [BNP Paribas Financial Markets Buys 21,115 Shares of Globe Life Inc. $GL](https://longbridge.com/en/news/288924594.md) - [Bank of New York Mellon Corp Sells 118,878 Shares of Globe Life Inc. $GL](https://longbridge.com/en/news/289149478.md) - [Caris Life Sciences Announces Share Repurchase Program | CAI Stock News](https://longbridge.com/en/news/289055468.md) - [Globe Life (GL) Valuation Check After Earnings Miss Guidance Raise And Analyst Downgrade](https://longbridge.com/en/news/287469894.md) - [Kymera Therapeutics, Inc. $KYMR Shares Sold by Atlas Venture Life Science Advisors LLC](https://longbridge.com/en/news/289658089.md)